About Revance Therapeutics
Revance Therapeutics is a company based in Newark (United States) founded in 2002 was acquired by Crown Laboratories in February 2025.. Revance Therapeutics has raised $154.56 million across 5 funding rounds from investors including Crown Laboratories, SVB Securities and Medicis Pharmaceutical. The company has 597 employees as of December 31, 2023. Revance Therapeutics has completed 1 acquisition, including HintMD. Revance Therapeutics offers products and services including DAXXIFY, Hyaluronic Acid Filler, and Microneedling Brand. Revance Therapeutics operates in a competitive market with competitors including Castle Creek Pharma, Dermavant, Sol-Gel Technologies, Bausch Health and Hugel, among others.
- Headquarter Newark, United States
- Employees 597 as on 31 Dec, 2023
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Revance Therapeutics, Inc.
-
Annual Revenue
$234.04 M77as on Dec 31, 2023
-
Net Profit
$-323.99 M9as on Dec 31, 2023
-
EBITDA
$-310.65 M1as on Dec 31, 2023
-
Total Equity Funding
$154.56 M (USD)
in 5 rounds
-
Latest Funding Round
$10 M (USD), Series E
Oct 22, 2013
-
Investors
Crown Laboratories
& 12 more
-
Employee Count
597
as on Dec 31, 2023
- Investments & Acquisitions
-
Acquired by
Crown Laboratories
(Feb 08, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Revance Therapeutics
Revance Therapeutics offers a comprehensive portfolio of products and services, including DAXXIFY, Hyaluronic Acid Filler, and Microneedling Brand. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Acetylcholine release inhibitor for treating glabellar lines in adults.
Product for aesthetic enhancements and skincare applications.
Device for skin rejuvenation and therapeutic applications.
Unlock access to complete
Unlock access to complete
Funding Insights of Revance Therapeutics
Revance Therapeutics has successfully raised a total of $154.56M across 5 strategic funding rounds. The most recent funding activity was a Series E round of $10 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series E — $10.0M
-
First Round
First Round
(12 Dec 2007)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2013 | Amount | Series E - Revance Therapeutics | Valuation |
investors |
|
| Feb, 2013 | Amount | Series E - Revance Therapeutics | Valuation | Delphi Ventures , EW Healthcare Partners |
|
| Jan, 2013 | Amount | Series D - Revance Therapeutics | Valuation | EW Healthcare Partners , NovaQuest Capital Management |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Revance Therapeutics
Revance Therapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Crown Laboratories, SVB Securities and Medicis Pharmaceutical. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in life sciences firms across all stages.
|
Founded Year | Domain | Location | |
|
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
|
Founded Year | Domain | Location | |
|
Investments are made in US life sciences and energy companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Revance Therapeutics
Revance Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include HintMD. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Users are connected to aesthetic physicians for customized treatment plans.
|
2014 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Revance Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Revance Therapeutics Comparisons
Competitors of Revance Therapeutics
Revance Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Castle Creek Pharma, Dermavant, Sol-Gel Technologies, Bausch Health and Hugel, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| domain | founded_year | HQ Location |
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Revance Therapeutics
Frequently Asked Questions about Revance Therapeutics
When was Revance Therapeutics founded?
Revance Therapeutics was founded in 2002 and raised its 1st funding round 5 years after it was founded.
Where is Revance Therapeutics located?
Revance Therapeutics is headquartered in Newark, United States. It is registered at Newark, New Jersey, United States.
Who is the current CEO of Revance Therapeutics?
Mark Foley is the current CEO of Revance Therapeutics.
Is Revance Therapeutics a funded company?
Revance Therapeutics is a funded company, having raised a total of $154.56M across 5 funding rounds to date. The company's 1st funding round was a Series D of $63.36M, raised on Dec 12, 2007.
How many employees does Revance Therapeutics have?
As of Dec 31, 2023, the latest employee count at Revance Therapeutics is 597.
What is the annual revenue of Revance Therapeutics?
Annual revenue of Revance Therapeutics is $234.04M as on Dec 31, 2023.
What does Revance Therapeutics do?
Revance Therapeutics was founded in 2002 and is headquartered in Newark, United States. Operations focus on the aesthetic medicine sector, where innovative neurotoxin products for skin treatments are developed. A proprietary platform technology is used to facilitate delivery of large macromolecules across the skin. The pipeline includes RT001 for lateral canthal lines and RT002 for glabellar lines, with applications extended to therapies for Hyperhidrosis and Cervical Dystonia.
Who are the top competitors of Revance Therapeutics?
Revance Therapeutics's top competitors include Dermavant, Bausch Health and Sol-Gel Technologies.
What products or services does Revance Therapeutics offer?
Revance Therapeutics offers DAXXIFY, Hyaluronic Acid Filler, and Microneedling Brand.
How many acquisitions has Revance Therapeutics made?
Revance Therapeutics has made 1 acquisition, including HintMD.
Who are Revance Therapeutics's investors?
Revance Therapeutics has 13 investors. Key investors include Crown Laboratories, SVB Securities, Medicis Pharmaceutical, Delphi Ventures, and EW Healthcare Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.